---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-25-007061"
form_type: "8-K"
ticker: "ADCT"
cik: "0001771910"
company_name: "ADC Therapeutics SA"
filed_at: "2025-06-05T23:59:59+00:00"
generated_at: "2026-05-19T22:24:26.178136+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# ADC Therapeutics elects Timothy Coughlin to board at 2025 AGM; all proposals pass

## Summary
- Timothy Coughlin elected to board; CPA, former Neurocrine CFO, appointed audit committee chair.
- Binding votes: board max comp $2.3M, exec fixed $2.6M, variable $3.5M.
- Amendment to 2019 Equity Incentive Plan approved to increase authorized shares.
- Articles of association amended to raise conditional share capital for employee participation.
- All 12 shareholder proposals, including director elections and say-on-pay, approved.

## SEC filing metadata
- accession: 0000950103-25-007061
- form_type: 8-K
- ticker: ADCT
- cik: 0001771910
- company_name: ADC Therapeutics SA
- filed_at: 2025-06-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771910/000095010325007061/0000950103-25-007061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771910/000095010325007061/dp229762_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-25-007061
- JSON: https://secwatch.observer/filing/0000950103-25-007061.json
- Plain text: https://secwatch.observer/filing/0000950103-25-007061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.